Marketa Zvelebil

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 739 citations · Full text

Pi3 Kinase, Chemoprevention Strategy, Pharmacotherapy +18

Wortmannin Inactivates Phosphoinositide 3-Kinase by Covalent Modification of Lys-802, a Residue Involved in the Phosphate Transfer Reaction

Matthias P. Wymann, Ginette Bulgarelli-Leva, Marketa Zvelebil et al. · Molecular and Cellular Biology · 1996 · 677 citations · Full text

Signal Transduction, Biochemistry, Natural Sciences +13

Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase.

Matthew J. Bottomley, E. Querfurth, Marketa Zvelebil et al. · The EMBO Journal · 1996 · 564 citations · Full text

Molecular Pharmacology, Distinct Specificity, Signal Transduction +12

Exploring the specificity of the PI3K family inhibitor LY294002

Severine Gharbi, Marketa Zvelebil, Stephen J. Shuttleworth et al. · Biochemical Journal · 2007 · 453 citations · Full text

Prediction of protein secondary structure and active sites using the alignment of homologous sequences

Marketa Zvelebil, Geoffrey J. Barton, William R. Taylor et al. · Journal of Molecular Biology · 1987 · 447 citations

Structural Bioinformatics, Biomolecular Structure Prediction, Protein Folding +14